FANCI Inhibitors
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a chemical inhibitor that indirectly influences FANCI by targeting the PI3K/AKT pathway. By inhibiting PI3K, LY294002 disrupts the signaling cascades that regulate FANCI expression and activation. This indirect modulation offers a tool for investigating the interplay between PI3K-dependent signaling and FANCI-mediated DNA repair processes. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a chemical inhibitor that indirectly modulates FANCI by targeting the PI3K/AKT pathway. It inhibits PI3K, disrupting the downstream signaling events that regulate FANCI expression and function. This indirect modulation provides a means to investigate the crosstalk between PI3K signaling and FANCI-mediated DNA repair processes. | ||||||
DNA-PK Inhibitor II | 154447-35-5 | sc-202143 sc-202143A | 10 mg 50 mg | $155.00 $660.00 | 6 | |
NU7026 (DNA-PK Inhibitor II) is a chemical inhibitor that indirectly influences FANCI by targeting the DNA-dependent protein kinase (DNA-PK). By inhibiting DNA-PK, NU7026 disrupts the DNA repair machinery, altering the interactions between FANCI and other repair factors. | ||||||
Olaparib | 763113-22-0 | sc-302017 sc-302017A sc-302017B | 250 mg 500 mg 1 g | $210.00 $305.00 $495.00 | 10 | |
AZD2281, also known as Olaparib, is a chemical inhibitor that indirectly modulates FANCI by targeting poly(ADP-ribose) polymerase (PARP). By inhibiting PARP, AZD2281 disrupts the DNA repair mechanisms involving FANCI. This indirect modulation provides a means to investigate the crosstalk between PARP-dependent signaling and FANCI-mediated DNA repair processes. | ||||||
ATM Kinase Inhibitor | 587871-26-9 | sc-202963 | 2 mg | $110.00 | 28 | |
ATM Kinase Inhibitor, KU-55933, is a chemical inhibitor that indirectly influences FANCI by targeting ataxia-telangiectasia mutated (ATM) kinase. By inhibiting ATM, KU-55933 disrupts the DNA damage response pathways, altering the recruitment and activation of FANCI. | ||||||
VE 821 | 1232410-49-9 | sc-475878 | 10 mg | $360.00 | ||
VE-821 is a chemical inhibitor that indirectly modulates FANCI by targeting ataxia-telangiectasia and Rad3-related (ATR) kinase. By inhibiting ATR, VE-821 disrupts the DNA damage response pathways, altering the recruitment and activation of FANCI. This indirect modulation offers a tool for investigating the interplay between ATR-dependent signaling and FANCI-mediated DNA repair processes. | ||||||
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $138.00 $380.00 | 101 | |
Cisplatin is a chemical compound that directly influences FANCI by inducing DNA damage. It forms DNA adducts, leading to the activation of the Fanconi anemia pathway, including FANCI. This direct modulation provides insights into the role of Cisplatin as a chemotherapeutic agent and its impact on FANCI-mediated DNA repair processes. | ||||||
Ceralasertib | 1352226-88-0 | sc-507439 | 10 mg | $573.00 | ||
AZD6738, an ATR inhibitor, indirectly modulates FANCI by targeting the ATR kinase. By inhibiting ATR, AZD6738 disrupts the DNA damage response pathways, altering the recruitment and activation of FANCI. This indirect modulation offers a tool for investigating the interplay between ATR-dependent signaling and FANCI-mediated DNA repair processes. | ||||||
Rucaparib | 283173-50-2 | sc-507419 | 5 mg | $150.00 | ||
Rucaparib is a chemical inhibitor that indirectly modulates FANCI by targeting poly(ADP-ribose) polymerase (PARP). By inhibiting PARP, Rucaparib disrupts the DNA repair mechanisms involving FANCI. This indirect modulation provides a means to investigate the crosstalk between PARP-dependent signaling and FANCI-mediated DNA repair processes. | ||||||
KU 60019 | 925701-46-8 | sc-363284 sc-363284A | 10 mg 50 mg | $248.00 $1035.00 | 1 | |
KU-60019 is a chemical inhibitor that indirectly influences FANCI by targeting ataxia-telangiectasia mutated (ATM) kinase. By inhibiting ATM, KU-60019 disrupts the DNA damage response pathways, altering the recruitment and activation of FANCI. | ||||||